Patient demographics and psychotropic medication prescribing in Australian general practices: pre- and during COVID-19 pandemic

Getiye Dejenu Kibret; Abbish Kamalakkannan; Judith Thomas; Gorkem Sezgin; Rae-Anne Hardie; Lisa Pont; Precious McGuire; Christopher Pearce; Andrew Georgiou

doi:10.1071/HC23168

RESEARCH ARTICLE (Open Access)

Previous Next Online Early

Patient demographics and psychotropic medication prescribing in Australian general practices: pre- and during COVID-19 pandemic

Getiye Dejenu Kibret

¹ ^* , Abbish Kamalakkannan ¹ , Judith Thomas ¹ , Gorkem Sezgin ¹ , Rae-Anne Hardie ¹ , Lisa Pont ² , Precious McGuire ³ , Christopher Pearce ¹ ⁴ , Andrew Georgiou ¹

+ Author Affiliations

- Author Affiliations

¹ Australian Institute of Health Innovation, Faculty of Medicine, Health and Human Sciences, Macquarie University, NSW 2109, Australia.

² Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Broadway, Sydney, NSW 2007, Australia.

³ Eastern Melbourne Primary Health Network, Vic., Australia.

⁴ Aurora Primary Care Research Institute, Vic., Australia.

^* Correspondence to: getiye.kibret@mq.edu.au

Handling Editor: Felicity Goodyear-Smith

Journal of Primary Health Care https://doi.org/10.1071/HC23168

Submitted: 6 December 2023 Accepted: 31 January 2024 Published: 19 February 2024

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)

Abstract

Introduction

Mental health conditions, such as depression, anxiety, and psychological distress in the adult population significantly increased during the COVID-19 pandemic. However, the rates of prescribing psychotropic medications in adults during the COVID-19 period have not been well explored.

Aim

The aim of this study was to examine the association between demographic characteristics and rates of prescribing psychotropic medications to general practice patients during 2018–2022.

Methods

A total of 154 528 general practice patients aged 20 years and above were included in the study. A mixed effects negative binomial regression model was employed and incidence risk ratios (IRRs) with corresponding 95% confidence interval (CI) are presented to measure the association of demographic characteristics with rates of prescribing psychotropic medication.

Results

Over half (56.2%) of study subjects were female and 41.4% were aged between 20 and 39 years. Males had lower prescribing rates of antidepressants (IRR = 0.95; 95% CI: 0.94, 0.97) and hypnotics and sedatives (IRR = 0.97; 95% CI: 0.96, 0.99) than females. People in the age group 60+ years (compared with age group 20–39 years) and those in low and middle socio-economic status (SES) categories (compared with high SES) had higher rates of prescribing psychotropic medication.

Conclusion

Females, people aged 60+ years, and people with low and middle SES had higher prescribing rates of psychotropic medication. A consistent increase in prescribing rates over time, particularly during the COVID-19 pandemic, was observed. It is important that health care planners and policy makers monitor and account for population diversity and equity.

Keywords: antidepressants, anxiolytics, COVID-19, demographic, general practice, prescriptions, primary care, psychotropics.

References

1 Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun 2020; 89: 531-542.
| Crossref | Google Scholar | PubMed |

2 Arjmand HA, Seabrook E, Bakker D, et al. Mental health consequences of adversity in Australia: national bushfires associated with increased depressive symptoms, while COVID-19 pandemic associated with increased symptoms of anxiety. Front Psychol 2021; 12: 635158.
| Crossref | Google Scholar | PubMed |

3 Brydon A, Bhar S, Doyle C, et al. National survey on the impact of COVID-19 on the mental health of Australian residential aged care residents and staff. Clin Gerontol 2022; 45(1): 58-70.
| Crossref | Google Scholar | PubMed |

4 Strutt PA, Johnco CJ, Chen J, et al. Stress and coping in older Australians during COVID-19: health, service utilization, grandparenting, and technology use. Clin Gerontol 2022; 45(1): 106-119.
| Crossref | Google Scholar | PubMed |

5 Australian Institute of Health and welfare. Mental health-related prescriptions. 2023. Available at https://www.aihw.gov.au/mental-health/topic-areas/mental-health-prescriptions

6 Tscharke BJ, Hollingworth S, van Driel ML, et al. The impact of COVID-19 on antidepressant sales and prescription dispensing in Australia. Aust N Z J Psychiatry 2022; 56(7): 871-872.
| Crossref | Google Scholar | PubMed |

7 Australian Institute of Health and welfare. Mental health-related prescriptions. 2021. Available at https://www.aihw.gov.au/mental-health/topic-areas/mental-health-prescriptions

8 Benistand P, Vorilhon P, Laporte C, et al. Effect of the COVID-19 pandemic on the psychotropic drug consumption. Front Psychiatry 2022; 13: 1020023.
| Crossref | Google Scholar | PubMed |

9 Hardie RA, Sezgin G, Pont LG, et al. Psychotropic medication prescribing for children and adolescents by general practitioners during the COVID‐19 pandemic. Med J Aust 2023; 219: 26-27.
| Crossref | Google Scholar | PubMed |

10 Pearce C, McLeod A, Rinehart N, et al. What a comprehensive, integrated data strategy looks like: the Population Level Analysis and Reporting (POLAR) program. Stud Health Technol Inform 2019; 264: 303-307.
| Crossref | Google Scholar | PubMed |

11 Department of Health. MMM: Modified Monash Model; Suburb and Locality Classification. Canberra, Australia; 2019. Available at https://www.health.gov.au/topics/rural-health-workforce/classifications/mmm

12 Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA) 2016 Technical Paper. 2018. Available at https://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001

13 Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge University Press; 2006.

14 Hyndman RJ, Athanasopoulos G. Forecasting: principles and practice. OTexts; 2018.

15 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2023. Available at https://www.R-project.org/

16 Simoni-Wastila L. Gender and psychotropic drug use. Med Care Jan 1998; 36(1): 88-94.
| Crossref | Google Scholar | PubMed |

17 Terlizzi EP, Norris T. Mental health treatment among adults: United States, 2020. NCHS data brief; no. 419. 2021. Available at https://stacks.cdc.gov/view/cdc/110593

18 Boyd A, Van de Velde S, Pivette M, et al. Gender differences in psychotropic use across Europe: results from a large cross-sectional, population-based study. Eur Psychiatry 2015; 30(6): 778-788.
| Crossref | Google Scholar | PubMed |

19 Ćurković M, Dodig-Ćurković K, Erić AP, et al. Psychotropic medications in older adults: a review. Psychiatr Danub 2016; 28(1): 13-24.
| Google Scholar |

20 ACSQHC. Joint Statement on the Inappropriate Use of Psychotropic Medicines to Manage the Behaviours of People with Disability and Older People. 2022. Available at https://www.agedcarequality.gov.au/news-publications/latest-news/joint-statement-inappropriate-use-psychotropic-medicines

21 Harrison SL, Sluggett JK, Lang C, et al. The dispensing of psychotropic medicines to older people before and after they enter residential aged care. Med J Aust 2020; 212(7): 309-313.
| Crossref | Google Scholar | PubMed |

22 Chen Y, Briesacher BA, Field TS, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170(1): 89-95.
| Crossref | Google Scholar | PubMed |

23 Lasserre A, Younès N, Blanchon T, et al. Psychotropic drug use among older people in general practice: discrepancies between opinion and practice. Br J Gen Pract 2010; 60(573): 156-162.
| Crossref | Google Scholar | PubMed |

24 Gallagher MW, Zvolensky MJ, Long LJ, et al. The impact of Covid-19 experiences and associated stress on anxiety, depression, and functional impairment in American adults. Cognit Ther Res 2020; 44(6): 1043-1051.
| Crossref | Google Scholar | PubMed |

25 Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med 2020; 383(6): 510-512.
| Crossref | Google Scholar | PubMed |

26 Tscharke BJ, Hollingworth S, van Driel ML, et al. The impact of COVID-19 on antidepressant sales and prescription dispensing in Australia. Aust N Z J Psychiatry 2022; 56(7): 871-872.
| Crossref | Google Scholar | PubMed |

27 Hirschtritt ME, Slama N, Sterling SA, et al. Psychotropic medication prescribing during the COVID-19 pandemic. Medicine 2021; 100(43): 27664.
| Crossref | Google Scholar | PubMed |

28 Leong C, Kowalec K, Eltonsy S, et al. Psychotropic medication use before and during COVID-19: a population-wide study. Front Pharmacol 2022; 13: 886652.
| Crossref | Google Scholar | PubMed |

29 ACSQHC: Australian Atlas of Healthcare Variation. Antipsychotic medicines dispensing, 65 years and over, from 2016–17 to 2020–21. 2021. Available at https://www.safetyandquality.gov.au/our-work/healthcare-variation/antipsychotic-medicines-dispensing-65-years-and-over-2016-17-2020-21

30 von Soest T, Bramness JG, Pedersen W, et al. The relationship between socio-economic status and antidepressant prescription: a longitudinal survey and register study of young adults. Epidemiol Psychiatr Sci 2012; 21(1): 87-95.
| Crossref | Google Scholar | PubMed |

31 Lesén E, Andersson K, Petzold M, et al. Socioeconomic determinants of psychotropic drug utilisation among elderly: a national population-based cross-sectional study. BMC Public Health 2010; 10(1): 118.
| Crossref | Google Scholar | PubMed |